MK-677 (Ibutamoren) + AOD-9604 Stack: Safety and Monitoring Guide

What MK-677 and AOD-9604 Each Do

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin mimetic that binds GHSR-1a and causes the pituitary to release GH in pulsatile bursts. AOD-9604 is a synthetic peptide of 16 amino acids corresponding to the C-terminal region (positions 176 to 191) of human growth hormone, modified with a tyrosine residue at the N-terminus to improve stability. They act at different points on the GH axis, and that separation is the pharmacological rationale for combining them.

MK-677: Oral GH Secretagogue

MK-677 does not inject GH directly. It amplifies the pituitary's own GH pulses by mimicking ghrelin. In a 12-month double-blind crossover trial in 24 healthy older adults (mean age 64 to 71), MK-677 at 25 mg/day raised 24-hour GH pulse amplitude by approximately 100% and increased serum IGF-1 into the young-adult range (target approximately 230 ng/mL) [1]. Appetite also increased, because GHSR-1a sits in hypothalamic circuits that regulate hunger. That appetite signal is dose-dependent and represents one of the most clinically noticeable side effects.

AOD-9604: Lipolytic GH Fragment

AOD-9604 was originally investigated as an anti-obesity agent by Metabolic Pharmaceuticals. Phase II trials showed dose-dependent reductions in body weight at 1 mg/kg/day oral dosing in obese adults, without the glucose-raising effects seen with full-length GH [2]. Because AOD-9604 lacks the GH receptor domains that drive IGF-1 production, it does not replicate GH's anabolic or diabetogenic properties at standard doses. Its primary activity is beta-3 adrenergic stimulation in adipose tissue, promoting fatty-acid oxidation.

Why the Combination Is Used

The theoretical appeal is additive body-composition remodeling: MK-677 elevates endogenous GH and IGF-1, supporting muscle protein synthesis and sleep quality; AOD-9604 targets adipose lipolysis through a separate receptor pathway. Because MK-677's IGF-1 elevation can mildly impair insulin sensitivity, some practitioners add AOD-9604 partly for its metabolically neutral fat-loss effect rather than escalating MK-677 dose further. This is a mechanistic argument, not a conclusion drawn from head-to-head trial data.

Evidence Quality for This Stack

No phase III or randomized controlled trial has examined MK-677 and AOD-9604 together. Rating the evidence honestly matters here, because the risks of overstating certainty in a growth-hormone-axis intervention are real.

What We Know from Separate Trials

For MK-677 alone: a two-year randomized, double-blind, placebo-controlled trial in 292 hip-fracture patients (mean age 79) found MK-677 25 mg/day raised IGF-1 by a mean of 84% and improved stair-climbing power by 24%, though it also increased peripheral edema (18% vs. 7% placebo) and congestive heart failure events in a frail subgroup [3]. Glucose tolerance worsened modestly.

For AOD-9604 alone: Phase II data showed the compound was well tolerated across doses from 1 mcg/kg to 9 mg/kg, with no significant change in fasting insulin, IGF-1, or glucose versus placebo at the therapeutic dose range [2]. A 24-week randomized trial in 300 obese patients found the 1 mg/kg/day oral group lost a mean 2.6 kg more than placebo, though that effect did not reach statistical significance in the primary endpoint.

Evidence Gaps

The combination has no published pharmacokinetic interaction data. Practitioners synthesize from the separate pharmacology, animal models, and self-reported outcomes in clinical populations. The FDA has not approved either agent for any indication in its current peptide form, and the FDA's 2023 guidance on compounded peptides places both compounds in a category requiring individualized provider oversight [4].

Dosing Protocol

This section outlines practitioner-reported protocols. Doses should be individualized based on baseline IGF-1, body composition goals, metabolic status, and provider judgment. These are not prescriptive recommendations.

MK-677 Dosing

• Starting dose: 10 mg orally at night. Taking it before sleep blunts the appetite surge and synchronizes the resulting GH pulse with natural nocturnal secretion.
• Titration: Increase to 25 mg at night after 4 weeks if IGF-1 remains below the age-adjusted upper quartile and fasting glucose is stable.
• Cycle length: Commonly 16 to 24 weeks on, followed by 8 to 12 weeks off to allow IGF-1 and ghrelin-receptor sensitivity to normalize. Continuous multi-year use appears in practitioner case series but lacks long-term safety data.

AOD-9604 Dosing

• Dose range: 250 to 500 mcg subcutaneously once daily, administered in a fasted state (at least 30 minutes before first meal or 2 hours after last meal).
• Injection timing: Morning, fasted. Some protocols split to 250 mcg morning plus 250 mcg pre-sleep.
• Cycle length: 12 to 16 weeks is the most commonly reported duration before reassessing body-composition response.

Stack Timing Considerations

MK-677 at night and AOD-9604 in the morning avoids direct pharmacokinetic overlap. MK-677's half-life is approximately 24 hours, so it maintains steady GHSR-1a occupancy throughout the day regardless of when AOD-9604 is injected. No pharmacokinetic data confirms a clinically meaningful interaction between the two compounds, but separating administration windows is a precautionary practice.

Safety Profile: MK-677

Insulin Resistance and Glucose

MK-677 consistently raises fasting insulin and can impair oral glucose tolerance. In a randomized, placebo-controlled crossover study in 24 healthy young adults, MK-677 25 mg/day for 14 days raised fasting blood glucose by a mean of 0.3 mmol/L and fasting insulin by approximately 39% [1]. For individuals with a baseline HbA1c above 5.6% or fasting glucose above 5.6 mmol/L, this represents a meaningful risk of tipping into impaired fasting glucose. Metformin 500 mg at night is sometimes co-prescribed to offset this, though that combination also lacks direct RCT support.

Fluid Retention and Edema

GH secretagogues cause sodium and water retention at the renal collecting duct. Peripheral edema affects roughly 10 to 18% of users at the 25 mg/day dose in clinical data [3]. Reducing to 10 to 12.5 mg generally resolves mild edema within 2 weeks. Patients with pre-existing cardiovascular disease or heart failure represent a contraindication to this agent.

Prolactin and Cortisol

Ghrelin mimetics increase ACTH and cortisol through hypothalamic stimulation. In one 2-week trial, MK-677 raised morning cortisol by approximately 22% [1]. Prolactin elevations are modest but measurable. Both parameters normalize after discontinuation. Screening for cortisol-dependent conditions (adrenal insufficiency, Cushing's disease) before starting is appropriate clinical practice.

Sleep Architecture

MK-677 deepens slow-wave sleep in most users. A randomized trial in older adults found statistically significant increases in REM sleep duration and improved sleep efficiency versus placebo [5]. This is one of the few benefits with direct controlled-trial confirmation.

Safety Profile: AOD-9604

Metabolic Neutrality

AOD-9604's primary safety advantage over full-length GH and over MK-677 is its lack of IGF-1 stimulation and its minimal effect on fasting glucose. Phase II data across more than 500 patient-exposures found no statistically significant difference in fasting glucose, HbA1c, or insulin sensitivity versus placebo [2]. This metabolic neutrality is what makes it potentially complementary to MK-677 rather than additive in terms of insulin risk.

Injection-Site Reactions

Subcutaneous injection of AOD-9604 produces mild, transient erythema and induration in approximately 5 to 10% of administrations based on phase II safety reporting. Rotating injection sites across the abdomen, lateral thigh, and flank minimizes this. Lipoatrophy at a single repeated site has been reported in case reports.

Antibody Formation

AOD-9604 is a synthetic peptide. Any exogenous peptide carries theoretical immunogenicity risk. Phase II data did not detect neutralizing antibodies over 24 weeks at therapeutic doses, but longer-term immunological data do not exist [2].

Safety Profile: Stack-Specific Considerations

Additive GH Axis Load

Both agents stimulate pathways that converge on increased GH activity in adipose and muscle tissue, even though they do not share a receptor. Running both simultaneously imposes a combined GH-axis load that neither compound's individual trials can fully characterize. IGF-1 should be kept within the age-adjusted normal reference range, not pushed above it. The Endocrine Society's clinical practice guideline on GH deficiency states that IGF-1 should be maintained at "the midnormal range for age" during any GH-axis intervention [6]. That principle applies here.

Cardiovascular Monitoring

The AGHD (adult growth hormone deficiency) evidence base suggests that physiologic GH restoration improves cardiovascular risk markers. However, supraphysiologic GH stimulation through secretagogues is not equivalent to replacement in GH-deficient patients. Blood pressure, resting heart rate, and electrocardiographic intervals should be checked at baseline and at 12 weeks. The 2021 American Heart Association/American College of Cardiology guidelines on cardiovascular risk reduction recommend addressing fasting glucose and lipid abnormalities before adding any agent known to worsen either [7].

Cancer Risk Consideration

IGF-1 is a mitogenic signaling molecule. Observational data from the UK Biobank (N=200,000+) show that IGF-1 levels above the 97th percentile associate with a modest increase in certain cancers, particularly colorectal and breast [8]. This is an association, not a proven causal pathway from pharmacologic IGF-1 elevation. Active malignancy or a personal history of hormone-sensitive cancer is an absolute contraindication to any GH secretagogue.

Monitoring Protocol

Systematic laboratory monitoring reduces the risk of undetected metabolic harm. The table below outlines a practical monitoring schedule.

| Timepoint | Labs / Assessments | |---|---| | Baseline (before starting) | IGF-1, fasting glucose, HbA1c, fasting insulin, lipid panel, CMP, CBC, prolactin, morning cortisol, blood pressure, body weight, DXA if available | | Week 4 | Fasting glucose, IGF-1, blood pressure, subjective edema and sleep assessment | | Week 8 to 12 | Full repeat of baseline panel plus injection-site assessment | | Week 16 to 20 (end of cycle) | Full panel, DXA if baseline was obtained, assessment of cycle-continuation decision | | 8 weeks post-cycle | IGF-1, fasting glucose, HbA1c to confirm return to baseline |

IGF-1 Targets

Target serum IGF-1 between the 50th and 75th percentile for age and sex, not above the upper limit of normal. In a 30-year-old male, that corresponds approximately to 150 to 250 ng/mL. Levels consistently above 300 ng/mL warrant dose reduction or cycle interruption.

Glucose Management

Fasting glucose above 6.1 mmol/L (110 mg/dL) on two measurements should prompt MK-677 dose reduction from 25 mg to 10 mg, or discontinuation if glucose remains elevated. HbA1c above 6.0% before starting represents a relative contraindication; above 6.5% is absolute.

When to Stop

Discontinue the stack and seek physician review if any of the following occur: fasting glucose exceeding 7.0 mmol/L, new or worsening peripheral edema, unexplained joint pain lasting more than 2 weeks, IGF-1 above the age-adjusted upper limit of normal on two consecutive draws, or signs of carpal tunnel syndrome (numbness and paresthesia in median nerve distribution).

Who Should Not Use This Stack

The following are contraindications drawn from each compound's individual safety data and from general GH-axis pharmacology:

• Active or recent malignancy (any type, due to IGF-1 mitogenicity)
• Uncontrolled type 2 diabetes or HbA1c above 6.5%
• Decompensated heart failure (MK-677 fluid retention risk)
• Active acromegaly or gigantism
• Age below 25 years (open epiphyseal plates, developing GH axis)
• Pregnancy or breastfeeding (no safety data)
• Pituitary tumors or hypothalamic pathology (unpredictable GH axis response)
• Current use of systemic corticosteroids (confounds cortisol monitoring and amplifies glucose effects)

Regulatory Status and Compounding Considerations

Neither MK-677 nor AOD-9604 holds FDA approval for human therapeutic use. MK-677 is classified as an investigational new drug; it was studied under NDA by Merck and Helsinn Therapeutics for muscle wasting but never received approval. AOD-9604 received FDA GRAS (Generally Recognized as Safe) designation for food use in 2014 [9], but that designation does not cover pharmaceutical compounding or injection.

Compounding pharmacies operating under 503A or 503B designations have provided both compounds to prescribing physicians. The FDA's December 2023 guidance on bulk drug substances placed several peptides under increased scrutiny. Providers and patients should verify that any compounded preparation comes from an FDA-registered 503B outsourcing facility with current USP <797> sterility certification.